| Pmab group N = 32 | Cmab group N = 43 | P-value |
---|---|---|---|
Sex | |||
 Male | 23 (72%) | 30 (70%) | 1.00 |
Age (years) | 65.7 (9.0) | 63.1 (12.4) | 0.33 |
Body weight (kg) | 58.1 (10.0) | 57.9 (9.0) | 0.91 |
Body surface area (kg/m2) | 1.62 (0.17) | 1.60 (0.16) | 0.59 |
Performance Status (ECOG) | |||
 0 / 1 / 2 | 15 (47%) / 16 (50%) / 1 (3%) | 27 (63%) / 15 (35%) / 1 (2%) | 0.39 |
Diabetes mellitus | 8 (25%) | 6 (14%) | 0.25 |
Smoking status | |||
 Never / former / current | 8 (25%) / 15 (47%) / 9 (28%) | 17 (40%) / 16 (37%) / 10 (23%) | 0.42 |
Serum albumin level (g/dl) | 3.64 (0.66) | 3.74 (0.36) | 0.43 |
Primary origin of tumors | |||
 Rectal / colon / other | 9 (28%) / 22 (69%) / 1 (3%) | 22 (51%) / 18 (42%) / 3 (7%) | 0.07 |
 On the left side of the colon / on the right side of the colona | 21 (66%) / 11 (34%) | 33 (78%) / 10 (23%) | 0.31 |
Line of treatment | |||
 1st / 2nd / 3rd | 25 (78%) / 6 (19%) / 1 (3%) | 38 (88%) / 4 (9%) / 1 (2%) | 0.47 |
Combined regimen | |||
 FOLFOX / FOLFIRI / LV5FU | 22 (69%) / 9 (28%) / 1 (3%) | 38 (88%) / 4 (9%) / 1 (2%) | 0.10 |
Concomitant bolus 5-FU | |||
 Presence / absence | 32 (100%) / 0 (0%) | 41 (95%) / 2 (5%) | 0.50 |
 Relative dose intensity in cycle 1 (%) | 97.3 (7.8) | 93.0 (21.6) | 0.28 |
Cetuximab intervalb | |||
 Weekly / biweekly | - | 13 (30%) / 30 (70%) | - |